Tesaro’s niraparib has been approved as a maintenance therapy for ovarian cancer in the US, although the company experienced a setback in its bid to develop the drug in breast cancer after ...

U.S. biopharmaceutical company Tesaro is discussing its options with investment banks after receiving acquisition interest from several drug makers, according to people familiar with the matter.

Tesaro’s ovarian cancer drug Zejula has been recommended by EU regulators, a competitor to AstraZeneca's trailblazing Lynparza. Zejula (niraparib), from the poly-adipose ribose polymerase (PARP ...